07:44 AM EDT, 07/01/2024 (MT Newswires) -- SpringWorks Therapeutics ( SWTX ) said Monday that it has submitted a new-drug application to the US Food and Drug Administration for mirdametinib to treat patients with neurofibromatosis type 1- associated plexiform neurofibromas, a rare genetic disorder.
The submission includes data from a phase 2b trial that evaluated mirdametinib in patients two years of age and older with type 1- associated plexiform neurofibromas causing significant morbidity.
Shares of SpringWorks Therapeutics ( SWTX ) were up more than 5% in recent premarket activity.
Price: 39.76, Change: +2.09, Percent Change: +5.55